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ABSTRACT 
 
The objective of this study is to optimize a nortryptiline hydrochloride patch 
previously designed (1) with the intended aim to develop controlled drug release 
system as a smoking cessation aid.  
Patches of 5%, 7.5% and 10% NTH concentrations were assayed for physical 
experiments. Measured thickness of the patches remains constant regardless of 
the NTH concentration. Obtained values are 31.88±5.0 µm, 32.33±5.1 µm and 
32.00±3.8 µm for 5%, 7.5% and 10% patch respectively. The variability is lower 
than 20 % in every case. Release and penetration studies were performed 
using Franz type of diffusion cells. The maximum cumulative amount released 
from assayed patches at 7 hours (last sampling point) varies as a function of the 
NTH concentration. Two kinetic models, power law and first order kinetics, are 
useful in order to predict the maximum amount to be released and the rate at 
which the process will be developed. Taking first order results into account, the 
maximum amount to be released (Qinf) is 7.185±0.30[mg/cm2]; 
12.359±0.69[mg/cm2]; and 29.333 ±1.97 [mg/cm2] for 5%; 7.5% and 10%patch 
respectively. Considering the power law fitting, the main conclusion is that the 
release mechanism is basically fickian diffusion as the exponent is about 0.5. 
Estimated permeation parameters are Kp=0.019·10-3±0.00 [cm/h]; 
t0=51.273±2.42[h] for 5% patch, Kp=0.004·10-3±0.00 [mg/cm]; 
t0=28.099±1.97[h] for 7.5% patch and Kp=0.005·10-3±0,00[mg/cm]; 
t0=26.312±1.98[h] for 10%patch. The lag time is decreases as the patch 
concentration is increased. Calculated flux is 0.834·10-6 and 1.291·10-6 
[mg2cm/g] for 7.5% and 10%patch respectively. Considering both parameters, 
flux and lug time, 10% patch is better dosage form than the other two.  
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ABSTRACT 
Předmětem této studie je optimalizace dříve navrhnutého filmu obsahujícího 
hydrochlorid nortriptylinu (HNT), s cílem vyvinout transdermální terapeutický 
systém s kontrolovaným uvolňováním, který by byl použit jako pomoc při 
odvykání kouření. 
Filmy s 5%, 7.5% respektive 10% obsahem HNT byly podrobeny fyzikálním 
zkouškám. Změřená tloušťka filmu byla konstantní, bez ohledu na koncentraci 
HNT. Obdržené hodnoty jsou 31.88±5.0 µm, 32.33±5.1 µm a 32.00±3.8 µm pro 
5%, 7.5% respektive 10% film. Ve všech případech je variabilita nižší než 20%. 
Studie penetrace a uvolňování HNT byly provedeny s použitím difusních cel 
Franzova typu. Maximální celkové množství uvolněné ze zkoušeného filmu 
v čase 7 hodin, (čas posledního odběru vzorku), se měnilo jako funkce 
koncentrace HNT obsaženého ve filmu. Dva kinetické modely, power law a 
kinetiku prvního řádu, lze použít na výpočet maximálního předpokládaného 
množství, které se uvolní (Qinf).  Pokud bereme v úvahu výsledky kinetiky 
prvního řádu, (Qinf) je 7.185±0.30[mg/cm2]; 12.359±0.69[mg/cm2]; a 29.333 
±1.97 [mg/cm2] pro 5%; 7.5% respektive 10%film. Vzhledem k tomu, že 
exponent power law nabývá hodnot okolo 0.5, lze dojít k závěru, že k 
uvolňování látky dochází prostou difusí. Parametry vyhodnocené pro permeaci 
jsou Kp=0.019·10-3±0.00 [cm/h]; t0=51.273±2.42[h] pro 5% film, Kp=0.004·10-
3±0.00 [mg/cm]; t0=28.099±1.97[h] pro 7.5% film a Kp=0.005·10-3±0,00[mg/cm]; 
t0=26.312±1.98[h] pro 10%film. Lag time se snižuje se zvyšující se koncentrací 
filmu. Vypočítaný flux (J) nabývá hodnot 0.834·10-6 1.291·10-6 [mg2cm/g] pro 
7.5% respektive 10% film. Pokud vezmeme v úvahu oba parametry, flux i lag 
time, 10%film je výhodnější dávkovací forma než film s obsahem HNT 5% 
respektive 7.5%.  
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1. INTRODUCTION 
 
The World Health Organization (WHO) reports that tobacco is the leading 
preventable cause of death in the world. In 2005, tobacco caused 5.4million 
deaths. At the current rate, the death toll is projected to reach more than 8 
million annually by 2030 and a total of up to one billion deaths in the 21st 
century. The smoking of cigarettes is one of the main risk factor for a number of 
chronic diseases, including cancer, lung disease, and cardiovascular diseases. 
Second-hand tobacco smoke is also dangerous to health. It causes cancer, 
heart diseases and many other serious diseases in adults. Almost half of the 
world’s children breathe air polluted by tobacco smoke, which worsens their 
asthma conditions and causes dangerous diseases. At least 200000 workers 
die every year due to exposure to second-hand smoke at work. In Europe 
millions of smokers want to stop smoking and many have tried to do so but 
have difficulty succeeding because tobacco use is such a powerful addiction.(2)  
The major inducer of tobacco dependence is nicotine, a tertiary amine with 
sympathomimetic activity. Nicotine was declared an addictive drug similar to 
heroin or cocaine. Nicotine itself is probably not responsible for most of the 
negative health consequences of smoking. Instead, persons who stop using 
nicotine-containing tobacco products experience an unpleasant withdrawal 
syndrome that may include such symptoms as depressed mood, disrupted 
sleep, irritability, frustration, anger, anxiety, difficulty concentrating, 
restlessness, decreased heart rate, and increased appetite or weight gain.(3) 
The extremely unpleasant nature of withdrawal from tobacco helps explain why 
many people who make an effort to stop smoking start up again.  
Tobacco dependence pharmacological treatment is at the moment based on 
two strategies: nicotine replacement therapy and non-nicotine therapy. Nicotine 
replacement products (gum, patch, nasal spray and inhaler) delivers nicotine in 
a way that allows an individual to reduce nicotine withdrawal symptoms. The 
other smoking cessation pharmacotherapy uses sustained-release bupropion, 
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an aminoketone antidepressant, that is hypothesized to aid smoking cessation 
by inhibiting dopamine reuptake in mesolimbic dopamine system.(4) 
There is a growing evidence, that nortriptyline hydrochloride, a tricyclic 
antidepressant, aids long-term smoking cessation. The evidence suggests that 
the mode of action is independent of its antidepressants effect and it is of 
similar efficacy to nicotine replacement.(5) There is also study showing that 
NTH permeates through the skin by passive diffusion.(1) Development of a 
transdermal drug delivery system (TDS) could be real alternative to oral 
administration offering a possible approach to overcome some of the drawbacks 
of systemic NTH oral therapy. Among the advantages of transdermal drug 
delivery system are also improving of patient compliance, assurance of 
essentially constant drug input and overcoming the gastrointestinal tract and the 
liver sites of metabolism that are responsible of the low oral bioavailability.  
The object of this study was to optimize a nortryptiline patch previously 
designed.(1) It is a (hydroxypropyl) methyl cellulose matrix prepared with 
mixture of water, ethanol and propylene glycol as solvent system and oleic acid 
and polysorbate as penetration enhancer. The effect of NTH concentration on 
the release and penetration characteristics is established. 
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2. THEORY 
 
2.1. STRUCTURE AND FUNCTION OF HUMAN SKIN 
The skin is a complex organ covering the whole surface of the body.  It is the 
largest organ of the body with a size of about 1.8 m2 and weights approximately 
4 kg. The thickness of the skin ranges from 1 mm to 4 mm.  It varies from place 
to place over the body. (6) 
Human skin provides an excellent barrier between the external environment and 
the body. It is a self repairing composite membrane which protects against 
physical, chemical, microbial, and radiological attack and performs a 
homeostatic role by controlling moisture and heat loss from the body. It also 
serves as a food reserve and sensory organ transmitting external environmental 
information.  
Human skin may be subdivided into three mutually dependent layers (Figure 1) 
including from top to bottom: a) the epidermis (and its associated appendages, 
pilosebaceous follicles and sweat glands); b) the dermis, separated from the 
epidermis by the dermal-epidermal junction, and c) the hypodermis. 
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Figure 1: Anatomy of the skin (http://www.rush.edu/rumc/images/ei0390.gif) 
 
2.1.1. The epidermis 
The epidermis (Figure 2) is the outermost layer of the skin with thickness 0.06 
to 0.1 mm. The cells of epidermis are arranged in continuous layers, comprising 
(from bottom to top):  
 the stratum basale (basal layer or stratum germinativum) 
 the stratum spinosum (spinous layer, princkle cell layer) 
 the stratum granulosum (granular layer) 
 the stratum corneum (horny layer) 
 
Figure 2:  The epidermis anatomy (http://z.about.com/d/dermatology/1/.jpg) 
 
The basal layer is a single layer of cubical or columnar, metabolically active 
cells. The principal cells of the basal layer are keratinocytes. The keratinocytes 
undergo cell division (via mitosis). On average, dividing basal cells replicate 
once every 200hours to 400 hours. After the replication, one daughter cell 
remains in the basal layer whilst the other migrates upwards through the 
epidermis towards the skin surface. The keratinocytes of the stratum basale are 
attached to the basement membrane by hemidesmosomes.  
Five to ten per cent of epidermal cells are non-keratinocytes, including mainly 
Langerhans cells and melanocytes.  
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Langerhans cells function as antigen-presenting cells in the skin’s 
immunological responses. Under the influence of melanocyte-stimulating 
hormone (MHS), melanocytes synthesize the pigment that gives the races of  
humans their unique skin colorations. Melanocytes are also set into action by 
ultraviolet radiation, leading to suntanning.  
The Merkel cell, other specialised cell type found within the basal layer, are 
associated with nerve endings. They have a role in cutaneous sensation. 
The cells of the spinous layer exhibit sharp surface protuberances and begin to 
synthesise keratines that aggregate to form tonofilaments. 
The major changes in cellular architecture occur in the granular layer. The cells 
of this layer continue to flatten and become much wider than underlying cells. 
The outermost layer of the skin, the stratum corneum (Figure 3), is the main 
element of the skin’s permeation barrier. (7) It is the end product of epidermal 
differentiation and consists of 15 to 25 cell layers over most of the body surface, 
though it is the much thicker over the palms and soles.(8) Each cell 
(corneocyte) is approximately 0.5 µm in thickness and 30 to 40 µm in width, the 
largest cell in epidermis. It contains no organelles but is filled with protein, 80 % 
if which is high molecular keratin (>60 000Daltons). The intercellular space is 
filled with lipids organized as bilayers. The stratum corneum has a very law 
water content, though it can take up to five times its weight in water when 
placed in a aqueous environment.(9) 
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Figure 3: Stratum corneum anatomy (http://z.about.com/d/dermatology/1/.jpg) 
 
The „brick and mortar model“(Figure 4) can be used to describe the structure of 
the horny layer. Corneocytes are the „bricks“ embedded in an intercellular lipid 
matrix of mainly fatty acids, ceramides, cholesterol and cholesterol sulfate.(10) 
Thus, the corneocytes are with a compound cell envelope, consisting of a highly 
insoluble, cross-linked protein inner surface and a hydroxyceramide monolayer 
outer surface. (11)  
The corneocytes are joined together by modified desmosomes and overlap with 
each other at their edges to form a mechanically strong layer. (12) 
The turnover time of the stratum corneum, the time for a newly formed cell to 
move from inside to outside and be sloughed, is approximately 14 days. (13) 
 
 
Corneocytes 
Intercellurar lipid 
matrix 
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Figure 4: Brick and mortar model  
2.1.1.1. Cutaneous metabolism  
The viable epidermis is the most metabolically active layer in skin and is 
capable of chemically modifying a variety of molecules. The metabolic 
processes catalyzed by the enzymes present in the skin include oxidation, 
reduction, hydrolysis, and conjugation.  
 
2.1.2. The dermis 
The dermis (or corium) is 3 to 5 mm thick and is composed of a matrix of 
connective tissue in which predominant bundles of collagen fibrils interlace with 
elastic tissue (approximately 4%) and sparse reticular fibers (approximately 
0,4%). This composite is embedded in an amorphous mucopolysaccharide 
ground substance comprising approximately 20% of the dermal mass. (7) 
The dermis encloses cutaneous appendages (ecrine sweat glands, apocrine 
glands, and pilosebacious units) and is penetrated by blood vessels, 
lymphatics, and nerves. The cutaneous blood supply has an essential function 
in regulation of body temperature. It delivers oxygen and nutrients to the skin 
while removing toxins and waste products; the vasculature is vital in repairing 
damaged skin. Capillaries reach to within 0.2 mm of the skin surface and 
provide sink conditions for most molecules penetrating the skin barrier (other 
than extremely lipophilic molecules). The blood supply thus keeps the dermal 
concentration difference across the epidermis provides the essential driving 
force for transdermal permeation. (14)  
2.1.3. The hypodermis 
This is a fatty tissue representing the deepest part of the skin. It plays an 
important role in thermoregulation, insulation, provision of energy (nutritional 
store) and protection from mechanical injuries.  
The main cells of the hypodermis are the adipocytes. Adipocytes are arranged 
in primary and secondary lobules.These lobules are separated by connective 
tissue septa containing cells (fibroblasts, dendrocytes, mastocytes ), the 
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deepest part of sweat glands, as well as vessels and nerves contributing to the 
formation of the corresponding dermal plexuses. 
2.1.4. Skin appendages 
Hair follicles and their associated sebaceous glands (pilosebaceous glands), 
eccrine glands, apocrine glands, and nail plates are referred to as the skin’s 
appendages. (7) 
 Hair follicles are found within the skin everywhere except the soles, the palms, 
the red portion of the lips and the external genitalia.  Collectively, hair follicles 
occupy about 1/1000 of the skin’s surface (15), a factor that sets a limit on the 
role they can play as a route of permeation.  Each hair follicle possesses one or 
more flasklike sebaceous glands. (16) The normal function of sebaceous glands 
is to produce and secrete sebum, a group of complex oils including triglycerides 
and fatty acid breakdown products, wax esters, squalene, cholesterol esters, 
and cholesterol. Sebum lubricates the skin to protect against friction and makes 
it more impervious to moisture. 
Eccrine or salty sweat glands are found over the entire body, except the 
genitalia. They are particularly concentrated in the palms and soles. (17) Ecrine 
sweat is dilute (hypotonic), slightly acidic (pH ≈ 5.0 owing to traces of lactic 
acid) aqueous solution of salt. (7) Eccrine sweat glands are the main sweat 
glands in humans, playing a vital role in the process of thermoregulation. Its 
secretion is stimulated when the body becomes overheated through warm 
temperatures or exercice. Evaporation of the water of the sweat cools the 
body’s surface and, therby, the body. Since the gland is innervated by 
autonomic nervous system, ecrine sweating is also stimulated emotionally. 
Apocrine glands have highly regionalize locations and are found only in the 
axillae, in anogenital regions, and around nipples. Bacterial decomposition of 
apocrine secretion is responsible for human body smell. (7)  
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2.2. PERMEATION PATHWAYS THROUGH THE STRATUM 
CORNEUM 
There are two general options for drug substances to permeate the stratum 
corneum: the transepidermal route and the transappendicular route. (18)   
The transepidermal route can be divided into the transcellular and the 
intercellular route. Using the transcellular route, the drug has to cross the skin 
by directly passing through both the lipid structures of the stratum corneum and 
the cytoplasm of the dead keratinocytes. This is the shortest route for the drug 
substance, but presents significant resistance to permeation because they have 
to cross both lipophilic and hydrophilic structures. The more common route for 
drugs to permeate the skin is the intercellular route. (19) In this case the 
permeant overcomes the stratum corneum by passing between the 
corneocytes, that implies a lipophilic pathway. The skin appendages (glands 
and hair follicles) occupy only 0.1% of the total human skin surface but the 
penetration thorugh it may also be an important pathway for the penetration of 
topically administered substances (20) as ions and polar compounds. (21) 
The percutaneous absorption is a spontaneous, passive diffusional process that 
takes the path of least resistance. Therefore, depending on the drug and the 
condition of the skin, either or both routes can be important. (22) 
 
2.3. THE PERCUTANEOUS ABSORPTION 
The absorption of substances from outside the skin to positions beneath the 
skin, including entrance into the blood stream, is referred to as percutaneous 
absorption.  
2.3.1. The process of percutaneous absorption 
The process of the percutaneous absorption (Figure 5) can be described as 
follows. When a drug system is applied topically, the drug diffuses passively out 
of its vehicle and, depending on where the molecules are placed they partition 
into either the stratum corneum or the sebum-filled ducts of the pilosebaceous 
glands. Inward diffusive movement continues from these locations to the viable 
epidermis and dermis. In this way, a concentration gradient is established 
across the skin up to the outer ends of the skin’s microcirculation, where the 
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drug is swept away by the capillary flow and rapidly distributed throughout the 
body. 
 
 
 
 
 
 
 
 
 
 
 DISSOLUTION OF DRUG IN VEHICLE  
      
DIFFUSION OF DRUG THROUGH VEHICLE TO SKIN SURFACE 
       
       TRANSEPIDERMAL ROUTE                      
  
TRANSFOLLICULAR 
ROUTE 
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  DIFFUSION THROUGH 
LIPIDS IN SEBACEOUS 
PORE 
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  VIABLE EPIDERMIS   
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EPIDERMIS 
  
      
  DIFFUSION THROUGH 
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DERMIS 
  
      
  CAPILLARY UPTAKE AND 
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Figure 5: The process of the percutaneous absorption  
 
2.3.2. Kinetics of absorption 
Transport across the skin is by passive diffusion only . This is a phenomenon by 
which a diffusant moves down a concentration gradient by random molecular 
motion. In the situation of a permeant entering the skin, diffusion is usually 
considered as unidirectional. This unidirectional diffusion in an isotropic medium 
can be expressed mathematically by Eq. (1), Fick’s second law of difusion, 
 
         
Eq. (1) 
 
where C is the concentration of the diffusing substance, x the space coordinate 
measured normal to the section, D the diffusion coefficient, and  t  the time. 
With skin permeation studies in vitro is often used a membrane clamped 
between two compartments, one containing a drug formulation (the donor) and 
the other a receptor solution providing sink conditions (essentially zero 
concentration), is often used. The  pemeability coefficient of a diffusant through 
a membrane, Kp, may be defined following the Scheuplein diffusion model as 
described below. This author demonstrated (23) by Eq. (2). 
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Eq. (2) 
 
The symbols used stand for: Q(t) (mg) is the quantity which passes through the 
membrane and reaches the receptor solution at a given time, t (min); A 
represents the actual diffusion surface area (cm2); P represents the partition 
coefficient of the permeant between the membrane and the donor vehicle; L , 
the membrane thickness (cm); D is the diffusion coefficient of the permeant in 
the membrane (cm2/h); and C is the concentration of the permeant (mg/ml). 
 
 After sufficient time, steady state diffusion across the membrane prevails. 
Under these conditions Eq. (1) may be simplified to Eq. (3). 
 
    
Eq. (3) 
      
where Q is the cumulative mass of permeant that passes per unit area through 
the membrane in time t; C0 is the concentration of diffusant in the first layer of 
the membrane at the skin surface contacting the source of the penetrant; and h 
is the membrane thickness.   
In most diffusion experiments, it is difficult to measure , but , the 
concentration of diffusant in the donor phase bathing the membrane, may be 
determined, because C0  and   are related, as shown by Eq. (4).  
 
           
Eq. (4) 
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where P  is  the partition coefficient of the diffusant between the membrane and 
the bathing solution. Substitution of Eq. (4) into Eq. (3) yields Eq. (5). 
       
Eq. (5)     
 
A graph of Q, the cumulative of drug crossing a unit area of skin, against time 
yields a profile of the drug penetrating the membrane. 
Extrapolation of the pseudo-steady-state portion of the graph to the intercept on 
the time axis provides the lag time (L). This is the period during which the rate 
of diffusion across the membrane is increasing. Steady-state conditions prevail 
after approximately 2.7 times the lag time. (24) The lag-time is related to the 
diffusion coefficient by Eq. (6).  
 
  
Eq. (6)          
 
Thus in theory, D may be obtained by measuring L, provided the membrane 
thickness, h, is known. In practice, this method for evaluating D has several 
disadvantages as the exact thickness of the stratum corneum is difficult to 
measure and may vary with penetration enhancer treatment. The measured 
thickness of the membrane does not allow for a tortuous pathway for diffusion 
and, for stratum corneum, the value obtained for D is therefore an apparent one. 
 
The pemeability coefficient of a diffusant through am membrane, Kp, may be 
defined by Eq. (7). 
 
          
 Eq. (7) 
 
which may be substituted into Eq. (4) to give Eq. (8).  
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Eq.(8) 
 
The expression dQ/dt , the rate of change of cumulative mass of diffusant that 
passes per unit area through the membrane, is termed the flux of diffusant, J, 
and may be evaluated from the steady-state portion of a drug permeation 
profile. Hence, Eq. (9) holds. 
 
        
Eq. (9) 
2.3.3. Factors affecting percutaneous absorption 
 
 Permeant properties 
Some authors have agreed about the optimum conditions to be a good 
candidate to percutaneous administration. They can be summarized as follows: 
 
 Low molecular weight (<600 Da), when its diffusion coefficient tends to 
be high 
 Adequate solubility in oil water-so that the membrane concentration 
gradient (the driving force for difussion) can be high. Saturated solutions 
(or suspensions having the same maximum thermodynamic activity) 
promote the maximum flux 
 A high, but balanced (optimal), partition coefficient (too large a value of 
K could inhibit the clearance by viable tissues) 
 Low melting point, correlating with good ideal solubility (25) 
 
 Variability of the skin  
A matter of considerable consequence in topical delivery is variability in skin 
pemeability between patients. Differ in age, gender, race and health, all of 
which are alleged to influence barrier function.  
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The senile skin, which tends to be dry, irritable, and poorly vascularized, is 
actually barrier compromised. (26) Gender, too, affects the appearance of 
human skin. Nevertheless, there is little evidence that the skins of male and 
female differ much in permeability. There are established differences in the 
barrier properties if skin across the races of man. Although the horny layers of 
whites and blacks are of equal thickness, the latter has more cell layers and is 
measurably denser. As a consequence, black skin tends to be less permeable. 
(27) 
 
Humidity and temperature also affect permeability. The skin hydratation 
increases skin permeability. The thermal activation alone can double the rate of 
skin permeability when there is 10º change in the surface temperature of the 
skin. (28) 
The health of the skin establishes its physical and physiological condition, and, 
thus, its permeability. Broken skin represents a high-permeability state, and 
polar solutes are several log orders more permeable when administered over 
abrasion and cuts. Irritation and mild trauma tend to increase the skin’s 
permeability, even when the skin is not broken. 
 
2.4. MODULATION OF SKIN PERMEATION 
The success of transdermal drug delivery systems depends on the ability of the 
drug to permeate skin in sufficient quantities to achieve therapeutic plasma 
levels. Unfortunately, many drugs do not posses, intrinsically, any great ability 
to cross the skin, and ways must be find to modify the barrier. This can be 
achieved chemically by the use of penetration enhancers or physically by the 
use of techniques such as iontophoresis or sonophoresis. 
 
 Chemical enhancement 
Substances reported to render the SC more permeable include alcohols, 
polyalcohols, pyrrolidones, amines, amides, fatty acids, sulphoxides, esters, 
terpenes, alkanes, surfactants and phospholipids. (29)  
There are different mechanism of action of these enhancers because of their  
structural diversity. For example, alcohols solubilize and extract the lipid 
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component of the SC to facilitate permeation. (30) Fatty acids are able to induce 
lipid fluidization as well as phase separation within the membrane. (31) By 
contrast simple hydration does not appear to affect lipid bilayer conformation or 
spacing. (32) 1-dodecylazacycloheptan-2-one (Azone®) is effective at low 
concentration and is thought to act by lipid fluidization as well as ionpairing. (33) 
 
 Physical penetration enhancement 
The iontophoresis technique applies a small electric current (usually <500 µA  
cm-2) to facilitate the transfer of drugs across the skin. (34) 
Phonophoresis or sonophoresis uses ultrasound energy for the skin penetration 
enhancement of drug 
2.5. TRANSDERMAL DRUG DELIVERY SYSTEM 
Transdermal drug delivery systems are designed to facilitate the passage of 
drug substances from the surface of the skin, through its various layers, and 
into the systemic circulation.  
Patch-type transdermal delivery systems are based on three design principles: 
 Drug in adhesive 
 Drug in matrix 
 Drug in reservoir 
In the last, the reservoir is separated from the skin by a rate-controlling 
membrane. 
Although  there are many differences in the design of transdermal drug delivery 
systems, several features are common to all systems including  
 the release liner 
 the pressure-sensitive adhesive 
 the backing layer 
all of which must be mutually compatible for a successful product. (35)  
The adhesives are usually based on silicones, acrylates, or polyisobutylene. 
(36) The adhesive must be soft enough to ensure initial adhesion, yet have 
sufficient cohesive strength to be removed cleanly, leaving no residue. 
  22 
A variety of materials can be used to fabricate the backing material and release 
liner. These include polyvinyl chloride, polyethylene, polypropylene, ethylene 
vinyl acetate and aluminium foil.  The main property of these materials is that 
they should be impervious to the drug and other formulation excipients. (37) 
Several materials can be used as rate-controlling membranes, examples being 
ethylene vinyl acetate copolymers, silicones, high-density polyethylene, 
polyester elastomers, and polyakrylonitrile. The membrane should be 
permeable only to the drug and the enhancer (if present) and should retain 
other formulation excipients. (38) In the matrix type is the drug uniformly 
dispersed in a polymeric matrix through which diffuses to the surface of the 
skin. (39) The polymeric matrix may be comprised of silicone elastomers, 
polyurethanes, polyvinyl alcohol, polyvinylpyrrolidones,etc. 
The drug reservoir is usually made from simple formulations such as mineral oil, 
to complex formulations such as aqueous alcoholic gels. A definite requirement 
for a reservoir system is that it should be capable of permitting zero-order 
release of the drug over the delivery period. This requires the reservoir material 
to be saturated with the drug over the period of product application, which can 
be achieved by formulation the drug as a suspension. 
Among the advantages of transdermal drug delivery systems are the following:  
 They are easy to apply, can remain on place for up to 7 days (depending 
on the system), and are easily removed following or during therapy.  
 The reduced dosing frequency and the production of controllable and 
sustained plasma levels tend to minimize the risk of undesirable side 
effects sometimes observed after oral delivery. (40) They avoid hepatic 
first-pass metabolism. Although the viable epidermis contains enzyme 
systems capable of metabolizing many drugs. (41) 
A major disadvantage of transdermal drug delivery system is the potential for 
localized irritant and allergic cutaneous reaction. (42)  
Modern TDS consist on self-adhesive matrices. Hydroxypropyl methyl cellulose 
is an atoxic polymer which provides transparent films with good organoleptic 
properties. It is also compatible with many cosolvents and enhancers used for 
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transdermal delivery. Besides that, the desired adhesiveness can be achieved 
by changing its concentration in the matrix. (5) 
 
2.5.1. Drug release from HPMC-based pharmaceutical 
systems 
The overall drug release mechanism from HPMC-based pharmaceutical 
devices depends on the design of the particular delivery system. The following 
phenomena are involved: at the beginning of the process, step water 
concentration gradients are formed at the polymer water interface resulting in 
water imbibition into the matrix. (43) Due to the imbibition of water swells 
resulting in dramatic changes of polymer and drug concentrations, and 
increasing dimensions of the system. Upon contact with water the drug 
dissolves and (due to the concentration gradients) diffuses out of the device. 
With increasing water content the diffusion coefficient of the drug increases 
substantially. (44)  
 
2.6. MOLECULE UNDER THE STUDY 
2.6.1. Pharmacological and pharmacokinetics of NTH 
Nortriptyline hydrochloride is a tricyclic antidepressant widely used in the 
treatment of unipolar depression. Besides that, there is growing evidence of its 
efficacy for smoking cessation pharmacological therapy. (45) In both 
indications, its mechanism of action consists of the inhibition of noradrenalin 
reuptake and, to a lesser extent, of 5-HT. Chronic administration induces beta-
receptor down-regulation. It presents a lower activity on alfa-adrenergic, 
histaminic and antimuscarinic than tertiary amines. 
Nortriptyline is well absorbed, a plasma peak occur 2±3 h after oral 
administartion and half-life is about 24±48h. Its metabolism is primarily by 
hepatic oxidation to 10-hydroxy-nortriptyline, which may contribute to 
therapeutic and toxic effects. This metabolite is excreted intact by the kidneys.  
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The most common side effects are dry mouth, sweating, constipation, asthenia, 
tachycardia, headache, somnolence and dizziness. (46) 
  
2.6.2. Physical-chemical properties 
Nortriptyline hydrochloride structure is represented in Figure 6. It has a 
molecular weight of 299.8. 
 
 
Figure 6: Nortriptyline hydrochloride 
It exhibits a pKa value of 9.73, due to the presence of the amino tertiary group.  
 It is very soluble in water. The solubility in phosphate buffer has been 
experimentally found to be dependent on the pH. The reported values are 
27.80±1.74 mg/ml at pH 5.5 and 0.72 ± 0.002 mg/ml at pH 7.4. It is soluble in 
alcohol and practically insoluble in ether. Its solubility in propylene glycol is 
366.8±1.90 mg/ml. (1) 
The lipophilicity of the tested substance measured as n-octanol partition 
coefficient pH of 5.5 for is 48.56±0.98. It has also been determined the partition 
coefficient beween HSE (heat separated epidermis) and the phosphate buffer 
pH 5.5 as 12.8±1.8. (1) 
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3. EXPERIMENTAL PART 
3.1. FILM PREPARATION 
A patch containing NTH was designed in a preliminary study. (1) It served as 
basis for the preparation of four different films with increasing concentration. 
3.1.1. The composition of assayed films 
The composition of films is shown in Table 1. The procedure to obtain a clear 
and uniform film is described underneath.  
 
COMPOUND 
 
PERCENTAGE (w/w) 
 
NTH 
 
5; 7.5; 10 or 15 
Ethanol 30 
Propylen glycol 30 
Oleic acid 1 
Polysorbate 80 1 
(Hydroxypropyl)methyl cellulose 2 
Distilled water adjusted to pH 5,5 c.s. 
 
Table 1: Composition of assayed films 
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3.1.2. Procedure of preparation 
A mixture of propylen glycol, ethanol and distilled water was prepared and NTH 
was dissolved in it under the stirring, with a speed of 500 rpm. The the solution 
was stirred for 5 minutes. Polysorbate 80 and oleic acid were incorporated and 
the mixture was stirred overnight. 
HPMC was weighted and slowly incorporated to the prepared vehicle increasing 
the stirring speed to 800 rpm. It was allowed to hydrate for 24 hours. The 
amount of polymer remained constant because it is well known that the change 
on the polymer content in the film can modify the diffusive mobility of the drug in 
the polymeric network. (47) 
Once it was fully hydrated and gel consistence was obtained, about 5 g of each 
preparation, exactly weighted, was placed into a Petri-dish, respectively about 
15 g, exactly weighted, was placed onto plate of glass (BIO-R) (Figure 7). Gel 
was dried for 4 hours into an oven. The preparation was weighted again after 
this drying and stored in vegetal paper, to evade the exposition of ambient. 
 
  27 
 
Figure 7: NTH film preparation 
3.2. FILM CHARACTERIZATION 
3.2.1. Film thickness 
The thickness of the films was measured at three different points (micrometer 
control super EWX 0-25mm Ezquerra Micra). Mean values were calculated and 
are reported. 
3.2.2. Film transparency 
The film once dried was visually controlled for transparency by means of 
superposition over the clear foundation with black printed letters. This is 
considered as a quality index. 
 
3.3. NTH IN VITRO DIFFUSION EXPERIMENTS 
Two types of diffusion experiments were performed: release studies and in vitro 
permeation studies.  
Both experiences were carried out using glass Franz type diffusion cells (FDC). 
Figure 8 schematically represents the setting. Two different FDC models were 
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used: one with an available diffusion area of 0.78 cm2 and 6 ml of receptor cell 
volume and another with an available diffusion area of 1.327 cm2 and 9ml of 
receptor volume. FDC were placed in heating/stirring module set at 350C to 
mimic the temperature of the skin surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DONOR COMPARTMENT    
RECEPTOR COMPARTMENT 
 
CLAMPS 
     PINZA 
SAMPLING 
HEATING MODULE (37OC) 
MAGNETIC BAR 
MEMBRANE 
MEMBRANE 
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Figure 8: Diffusion cell, Franz type 
http://www.scfonline.com/english/37_e/images37_e/Skinpenetration37_11
_small.jpg 
 
3.3.1. Buffer preparation 
The receptor compartment was filled with phosphate buffer 1/15 M. The buffer 
is prepared as mixture 96:4 (V/V) of solution A and B. The buffer was adjusted 
to pH 5.5.  
 Solution A  
It was prepared by dissolving 9.073g of NaH2PO4 in 1000 ml of water HPLC 
grade.  
 Solution B  
This solution was prepared by dissolving 11.87g of Na2HPO4 in 1000 ml of 
water HPLC grade. 
 
3.3.2. In vitro drug release study 
The release of drug from film preparation was examined using FDC described 
above. The receptor compartment was filled with phosphate buffer 1/15 pH 5.5 
solution free of air bubbles. A 25 mm circle of membrane (Millipore® 
nitrocelulose 0.45µm) was sandwiched between donor and receptor 
compartment. Prepared FDC were stabilized by clamps, placed in water bath 
(Figure 10) maintained at 350C and continually stirred by a magnetic bar at 500 
rpm. After 10 min, cells were dosed by pressing sample patches onto the 
membrane. Parafilm or caps occluded the donor and receptor chambers 
respectively to prevent evaporation of volatile components. (48) Samples of 200 
µL were withdrawn at specified intervals from the receptor compartment.  The 
same volume of fresh buffer was replaced in the receptor after sampling.   
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Figure 10: FDC in the heating/stirring module 
 
3.3.3. In vitro skin penetration study 
The penetration profile of NTH from film preparation was examined using FDC 
described above. The experimental conditions were the same as in vitro drug 
release study except for the type of membrane, that was heat-separated 
epidermis (HSE) obtained as described below. The skin pieces were mounted 
over the diffusion cells with the stratum corneum side in contact with the donor 
compartment and the dermal side over a dialysis membrane circle situated on 
the receptor compartment. The sampling was carried out every 90 min for a 
total of 72 h.  
3.3.3.1. Skin sample preparation 
Experiments were performed on abdominal skin samples from female donors 
aged 38 to 48 years, obtained after cosmetic surgical corrections performed in 
the Hospital 9 de Octubre (Valencia, Spain). Informed consent was previously 
obtained from the patients. Their identity was masked to the researchers to 
guarantee their anonymity.  
Immediately after surgery, the skin was transported to the laboratory, where the 
excess fatty and connective tissues were carefully excised. The skin was cut 
into pieces with sufficient size for experiments. Damaged areas, with stretch or 
other marks, were left out because the experiments must be carried out with 
completely uniform samples. These pieces were   wrapped in aluminium foil and 
stored in a freezer bags in freezer at -40º C for less than three months.  
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When required, the skin was removed from the freezer and left at room 
temperature (25oC) to defrost for 1 to 2 hours.  Epidermal membranes were 
prepared by a heat-separation technique. (49) The piece of skin was extended 
on a silicon plate and then it was fixed with needles. The plate with skin was 
sunk in distilled water kept at 60 ºC, for 45 s. This temperature debilitates the 
epidermis and dermis junction.  
After 45s , the skin was took out of the bath and put into Petri dish containing  
0.9% isotonic solution of NaCl (30 s approximately)  to cool and to remove the 
rest of debris. Immediately after the epidermis was carefully separated from the 
underlying dermis (Figure 9). Circular discs of diameter 25mm were cut out and 
gently located on a filter paper (Whatman n01). 
 
Figure 9: Separation of epidermis  
3.3.3.2. Test of membrane integrity  
Integrity of the epidermis was tested at the end of in vitro penetration 
experiments by means of the phenol red test. It consists of adding 400 µl of 1% 
phenol red solution into the donor compartment. The receptor compartment 
changed the color (Figure 10) if the membrane was damaged. The entire set of 
samples obtained from this cell was discarded in this case. 
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Figure 10: Phenol red test 
 
3.4. ANALYTICAL METHOD FOR NTH DETERMINATION 
NTH analysis was performed by high performance liquid chromatography.  
3.4.1. HPLC equipment 
The chromatographic system consisted of a isocratic bomb Waters model 1515, 
automated sample injector Perkin-Elmer series 200, UV detector Waters model 
2487 and software Breeze 3.2® (Waters Co).  
3.4.2. The mobile and stationary phase 
The mobile phase was a mixture of acetonitrile HPLC grade (Scharlau) and 
phosphoric acid solution at 50/50 V/V. 
The phosphoric acid solution was prepared by dissolving 1.17 g of NaH2PO4 in 
distilled water HPLC grade. The solution was adjusted to pH 3. 
A Kromasil®RP-18 (150x4 mm, 5 µm) column a stationary phase was used as 
stationary phase. 
3.4.3. Condition of analysis 
The injection volume was 25 µl of each sample. The flow rate was 1. 0 ml/min. 
The wavelength of 254 nm was employed. Analysis was realized at ambient 
temperature. In these conditions, the retention time of NTH was about 2.3 min.  
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3.4.4. Method validation 
The HPLC method was validated for linearity, accuracy and precision. 
The linearity was checked by the determination coefficient of the linear 
regression of areas versus concentration, which represents the percentage of 
the response variability that can be explained by concentration. The significance 
of the regression is also demonstrated by F test that is provided by Excel®. 
Accuracy was measured by the relative error calculated on three standards 
(low, medium and high concentration). Four replicates of every standard were 
injected onto HPLC on different days of analysis. It is reported as the maximum 
value and should be lower that 10 % and independent on the concentration. 
Precision is established by the coefficient of variation of a set of four replicates, 
analysed on different days. Three levels of concentration were used (low, 
medium and high). In order to guarantee the quality of results it must be below 
10%.  
The limit of determination was also determined to ensure the appropriateness of 
the method for our experimental conditions. It was calculated as 3.3 times the 
standard deviation of the intercept divided by the slope of regression line. 
 
3.5. MATHEMATICAL METHODS 
The results are expressed as media and standard deviation, calculated by 
means of Excel 7.0. The variability is also reported as variation coefficient when 
appropriate. Linear regression was used for calibration curves. It was performed 
by means of Excel 7.0. The goodness of the fits was evaluated by the 
coefficient of determination (r2) and the signification of the slope. 
Nonlinear regression analysis was used to estimate the parameters of drug 
release and drug penetration across HSE. Sigmaplot 10.0 was used as 
software. No weighting scheme was used.  
Akaika criterion was used to compare the goodness of the fit of the different 
kinetic models of release. 
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3.6. Determination of release parameters 
Concerning drug release, the cumulative amounts of NTH versus time were 
plotted and its kinetics was characterized by fitting the Power law equation 
(Eq.10) and First order equation (Eq.11) to data. (44) 
 
Eq. 10 
 
Eq. 11 
 
In these equations, Qt and Qinf stand for the absolute cumulative amount of drug 
released at time t and infinite time, respectively, k represents a constant 
incorporating structural and geometric characteristics of the matrix, and n is the 
release exponent, indicative of the mechanism of drug release. 
3.7. Determination of permeation parameters 
In the case of permeabilty characterization, the cumulative amount of drug 
permeated through the skin was plotted as a function of the time. The 
permeability coefficients, Kp and lag time, tL, were calculated following the 
Scheuplein diffusion model (Eq.12) . 
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Eq. 12 
 
The symbols used stand for: Q(t) (mg) is the quantity which passes through the 
membrane and reaches the receptor solution at a given time, t (min); A 
represents the actual diffusion surface area (cm2); P represents the partition 
coefficient of the permeant between the membrane and the donor vehicle; L , 
the membrane thickness (cm); D is the diffusion coefficient of the permeant in 
the membrane (cm2/h); and C is the concentration of the permeant (mg/ml). In 
order to estimate Kp and tL as primary parameters, equation 1 was transformed 
by substituing P D/L by Kp and L
2/6D by tL. The fitting equation (Eq.13) was: 
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Eq. 13 
The symbols have already been described. 
The flux was calculated using the following expresion (Eq.14): 
J=Kp·ΔC·A 
Eq. 14 
In which J stands for flux, ΔC represents the concentration gradient during the 
experiment and A is the diffusion area. Considering that conditions were 
representative of infinite dose experiments, it is assumed that, the concentration 
in the donor doesn’t change more than 10% and therefore, it can be considered 
to be constant; the receptor phase is considered to be a sink, so that, ΔC, can 
be substituted by the concentration of the donor compartment.  
 
 
 
 
 
 
4. RESULTS AND DISCUSSION 
 
Patches of four different NTH concentrations were prepared and assayed for 
the release and penetration behavior. The results are described below along 
with the interpretation data. The patch of 5 %, 7.5 % 10 % and 15 %. The patch 
of 15 % has precipitated, consequently wasn’t submitted to experiments. The 
appropriate patches were characterized by measuring its thickness. Film 
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transparency was also controlled. In vitro drug release and in vitro skin 
penetration study were performed using FDC. 
4.1. VALIDATION OF THE ANALYTICAL METHODOLOGY 
The HPLC method was validated for accuracy (9.6 as the highest relative error 
obtained), precision (2.7% as the highest variation coefficient) and linearity over 
the concentration range analyzed (r2>0.999). The limit of determination was 
50ng/ml.  
4.2. FILM CHARACTERIZATION 
The procedure for the preparation of the patch of 5%, 7.5%, 10% and 15% was 
similar. Nevertheless, during the desiccation process the 15% NTH patch 
precipitated, and consequently wasn’t subjected to further experiments. 
Patches with adequate organoleptic characteristics had their thickness 
measured at three different points of each patch. Three replicates were 
evaluated. The different measurements are listed in Table 2, along with the 
mean and standard deviation calculated.  
 
 
Thickness 
[µm] 
Patch 
concentration 
Measurement number 
Mean±SD 
1 2 3 
5% 
25 27 31 
31.88±5.0 30 35 38 
27 36 38 
7,5% 
30 29 26 
32.33±5.1 35 33 43 
29 36 30 
10% 
34 30 35 
32.00±3.8 30 27 27 
32 35 38 
 
Table 2:Thickness of the patch [µm]. SD: standard deviation 
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As can be observed, this parameter remains constant regardless of the NTH 
concentration of the gel used to prepare the film. The variability is lower than  
20 % in every case. 
 
The amount of drug loaded in every type of patch was calculated and 
expressed as the ratio per area. The results are shown in Table 3. 
Q total 
[mg/cm2] 
Patch 
concentration 
Patch number 
Mean±SD 
1 2 3 
5% 16.010 13.432 13.861 14.434±1.38 
7.5% 18.810 21.505 22.293 20.869±1.83 
10% 30.188 29.619 29.006 29.604±0.59 
 
Table 3: Amount of NTH present in the different patches. SD: standard 
deviation. 
 
Film transparency was also controlled. It was checked visually and confirmed 
for every patch prepared. By means of physical experiments, transparency 
observation and thickness measurement, it can be concluded that the films are 
homogenous.  
 
4.3. CHARACTERIZATION OF THE RELEASE PROCESS 
Drug release from the pharmaceutical dosage forms is a determinant parameter 
in in vivo performance, so that it should be studied in the design and 
development process of transdermal systems. 
The experiences of release were performed with the three different patches 
assayed. The cumulative amounts released [mg/cm2] from them are showed in 
Tables 4 to 6. Every table presents the raw data of the four replicates and the 
average and the standard deviation at each time point. The results are 
graphically outlined in Figures. 
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5%patch 
t(min) 
Cumulative amount released 
Q [mg/cm2] 
Mean  
cumulative 
amount±SD 
1 2 3 4 
10 1.161 0.760 0.778 0.584 0.821±0.24 
20 3.099 1.415 1.394 1.520 1.857±0.83 
30 3.426 2.284 1.880 2.173 2.441±0.68 
40 3.916 2.909 2.407 2.894 3.032±0.63 
60 4.595 3.595 2.691 3.548 3.607±0.78 
120 6.168 5.555 3.804 4.820 5.087±1.02 
180 6.672 6.374 4.636 5.626 5.827±0.91 
265 8.805 7.282 5.337 7.129 7.138±1.42 
360 - 7.128 5.911 7.552 6.864±0.85 
420 - 7.342 5.887 7.865 7.031±1.02 
 
Table 4: Cumulative amount of NTH released from 5% HPMC patch at the 
sampling times; mean, SD:standard deviation 
 
7.5%patch 
t(min) 
Cumulative amount released 
Q [mg/cm2] 
Mean  
cumulative 
amount±SD 
1 2 3 4 
10 2.099 0.400 0.849 1.017 1.091±0.72 
20 3.357 1.588 2.021 2.248 2.304±0.75 
30 4.616 2.148 3.333 3.675 3.443±1.02 
40 4.836 3.000 4.487 4.841 4.291±0.88 
60 5.806 3.891 5.418 5.102 5.054±0.83 
120 7.703 6.363 6.621 6.544 6.808±0.61 
180 9.102 8.665 6.933 6.732 7.858±1.20 
265 11.280 11.036 7.257 7.690 9.316±2.14 
360 - 11.764 7.092 7.542 9.180±2.58 
420 - 12.350 7.622 8.707 9.560±2.48 
 
Table 5: Cumulative amount of NTH released from 7.5% HPMC patch at the 
sampling time; mean, SD: standard deviation 
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10%patch 
t(min) 
Cumulative amount released 
Q [mg/cm2] 
Mean  
cumulative 
amount±SD 
1 2 3 4 
10 1.414 3.476 1.020 1.12 1.757±1.16 
20 6.160 5.659 2.309 2.81 4.234±1.96 
30 9.047 7.467 3.591 4.62 6.180±2.52 
40 10.516 8.442 5.129 6.10 7.546±2.42 
60 12.461 10.070 6.772 7.87 9.293±2.52 
120 16.207 13.344 11.137 13.23 13.479±2.08 
180 18.836 15.900 13.982 0.68 12.349±8.03 
265 20.363 21.412 16.858 32.35 22.745±6.69 
360 - - 17.620 19.98 18.802±1.67 
420 - - 17.860 19.22 18.538±0.96 
 
Table 6: Cumulative amount of NTH released from 10% HPMC patch at the 
sampling time; mean, SD: standard deviation 
 
The maximum cumulative amount released at 7 hours (last sampling point) 
varies as a function of the NTH concentration in the patch. It is always lower 
than the estimated content: 47%, 52% and 33% for 5%, 7.5% and 10% patch 
respectively). There is not a clear relationship between percentage released 
and patch concentration. The explication of this result could be a possible 
retention of NTH by the matrix of HPMC.  
Two different kinetic models were fitted to the obtained data in order to get an 
insight into the mechanism underlying the process of release. They correspond 
to the first order kinetics and the power law, as described in the Experimental 
part section. The parameters estimated are presented in Table 7 to 9, along 
with the figures representing the goodness of the fit. The results are graphically 
presented in the Figures no 11 to 13, as a blue or red line (first order or power 
law fitting, respectively).  
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5% patch release kinetics 
First order Qinf±S.E. 
[mg/cm2] 
k±S.E. 
[h-1] 
r2 AIC 
7.849±0.60 0.017±0.00 0.922 -33.251 
7.381±0.09 0.012±0.00 0.998 -69.309 
5.777±0.20 0.011±0.00 0.979 -53.468 
7.732±0.29 0.009±0.00 0.982 -48.995 
Naive averaging data: 
Qinf=6.968±0.18[mg/cm2]; k=0.013±0.00[h-1]; r2>0.986 
 
Standard two stage method:  
Qinf: 7.185±0.30[mg/cm2]; k= 0.012±0.00[h-1] 
Power law Kd±S.E. n±S.E. r2 AIC 
0.045±0.01 0.445±004 0.967 -40.228 
0.043±0.01 0.439±0.05 0.936 -36.585 
0.032±0.00 0.442±0.03 0.981 -54.840 
0.033±0.01 0.484±0.03 0.977 -46.536 
Naive averaging data: 
Kd=0.043±0.01; n=0.413±0.04; r>0.952 
 
Standard two steps method:  
Kd: 0.038±0.01; n: 0.453±0.04 
 
Table 7: Parameter describing release kinetics: Qinf-predicted amount 
released at infinite time; k first order release constant;  r2-determination 
coefficient; AIC-Akaike criterion, kd-diffusive constant; n-release exponent 
of the power law equation S.E.-standard error of the parameters. 
 
7,5% patch release kinetics 
First 
order 
Qinf±S.E. 
[mg/cm2] 
k±S.E. 
[h-1] 
r2 AIC 
20.675±1.97 0.003±0.00 0.907 -22.534 
13.736±0.35 0.006±0.00 0.998 -67.078 
7.307±0.17 0.020±0.00 0.984 -61.200 
7.719±0.29 0.019±0.00 0.956 -50.214 
Naive averaging data: 
Qinf=9.135±0.34[mg/cm2]; k=0.014±0.00[h-1]; r2>0.984 
 
 
Standard two steps method:  
Qinf: 12.359±0,69[mg/cm2]; k=0.012±0.00[h-1] 
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Power 
law 
Kd±S.E. n±S.E. r2 AIC 
0.054±0.00 0.424±0.01 0.997 -57.522 
0.015±0.00 0.617±0.05 0.980 -46.159 
0.054±0.02 0.325±0.06 0.848 -38.745 
0.052±0.01 0.343±0.05 0.906 -42.654 
Naive averaging data: 
Kd=0.031±0.01; n=0.400±0.04; r>0.946 
 
Standard two steps method:  
Kd= 0.044±0.01; n=0.427±0.04 
 
Table 8: parameter describing release kinetics: Qinf-absolute cumulative 
amount released at infinite time; r2-confidence interval; AIC-Akaike 
criterion, kd-diffusive constant; n-release exponent of the power law 
equation S.E.-coefficient standard error 
 
 
 
 
 
 
 
 
 
 
 
 
10% patch release kinetics 
First order Qinf±S.E. 
[mg/cm2] 
k±S.E. 
[h-1] 
r2 AIC 
36.468±4.13 0.004±0.00 0.862 -15.708 
41.523±3.08 0.003±0.00 0.951 -24.255 
18.968±0.27 0.007±0.00 0.999 -70.644 
20.374±0.39 0.009±0.00 0.997 -50.570 
Naive averaging data: 
Qinf=18.721±0.65[mg/cm2]; k=0.012±0.00[h-1]; r2>0.995 
 
 
Standard two steps method:  
Qinf=29.333±1.97[mg/cm2]; k=0.006±0.00[h-1]  
Power law Kd±S.E. n±S.E. r2 AIC 
0.071±0.01 0.407±0.02 0.979 -34.306 
0.053±0.01 0.456±0.02 0.989 -38.864 
0.024±0.01 0.552±0.05 0.962 -38.687 
0.029±0.01 0.528±0.06 0.960 -30.596 
  42 
Naive averaging data: 
Kd=0.045±0.02; n=0.455±0.08; r>0.844 
 
Standard two steps method:  
Kd=0.044±0.01; n=0.486±0.04 
 
Table 9: parameter describing release kinetics: Qinf-absolute cumulative 
amount released at infinite time; r2-confidence interval; AIC-Akaike criteria, 
kd-diffusive constant; n-release exponent of the power law equation S.E.-
coefficient standard error, 
 
As can be observed there is not a general best model to describe the data. Both 
are useful in order to predict the maximum amount to be released and the rate 
at which the process will be developed. On the other hand, two different 
approaches have been used to describe the whole batch, i.e. naïve averaging 
data (NAD) and standard two steps (STS) fitting method. The NAD method was 
applied to data fitting the equation to the mean amount released at every 
sampling time, even though the variability between replicates was relatively high 
(maximum value of 22.9%, 24.2% and 33% for 5%, 7.5% and 10% patch, 
respectively). STS method has the advantage of establishing the inter-subject 
variability of parameter estimations, which are quite low in this case. Both 
method estimate very similar parameters characterizing the release process. 
Considering the 5%patch from a statistical point of view (i.e. Akaike criterion), 
two replicates are slightly better described by the power law equation and the 
other two for first order kinetics. If first order results are taken into account, the 
maximum value to attain represents about 7 mg/cm2, regardless of the fitting 
approach used. The release first order constant is estimated as 0.012 h-1. This 
means that 57.7h would be needed to release the maximum amount. These 
data are in accordance with the low percentage of NTH released from the 
patch. Considering the power law equation, result obtained with 5% patch show 
that release mechanism is basically fickian diffusion as the exponent is between 
0.45 and 0.5, which are representative of a cylinder and a film respectively. This 
fact explains good results obtained when applying the first order equation. 
Moreover, the fact can be explained considering that the patches obtained were 
not completely flat (31.88µm). 
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In consideration to the 7.5% patch from a statistical point of view (i.e. Akaike 
criterion) one replicate is slightly better described by the power law equation 
and the other three for first order kinetics. If first order results are taken into 
account, the maximum value to attain represents about 12mg/cm2, in reference 
to STS method. The release first order constant is estimated as 0.012 h-1. This 
means that 57.7h would be needed to release the maximum amount. As 
mentioned above, it is in accordance with the low percentage of NTH released 
from the patch. The release mechanism is basically fickian diffusion, the 
exponent is also above 0.4 to 0.6. 
In reference to 10% patch, two replicates are slightly better described by the 
power law equation and the other two for first order kinetics, from a statistical 
point of view (Akaike criterion). If first order results are taken into account, the 
maximum value to attain in release represents about 29 mg/cm2, in regard to 
STS method. The release first order constant is estimated as 0.06 h-1, it  means 
that 115.5 hours would be needed to release the maximum amount. It is in 
accordance with the low percentage released from the patch. The release 
mechanism is basically fickian diffusion, as the exponent is between 0.4 to 0.5.   
 
NTH release; 5% patch 
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Figure 11: in vitro drug release of NTH from 5% patch in static Franz diffusion 
cells. 
 
 
 
 
NTH release; 7.5% patch 
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Figure 12: in vitro drug release of NTH from 7.5% patch in static Franz diffusion 
cells. 
 
 
 
 
 
NTH release; 10% patch 
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Figure 13: in vitro drug release of NTH from 10% patch in static Franz diffusion 
cells. 
 
 
 
 
4.4. CHARACTERIZATION OF PENETRATION THROUGH HSE 
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The cumulative amount of NTH that penetrated through HSE discs was 
calculated for each sampling time as described in Experimental part section. 
The Scheuplein equation was fitted to the obtained data. Only the STS method 
was used as the sampling time was not homogeneous. The estimated 
parameters by this method are presented in Table 10, along with the figures 
representing the goodness of the fits. The figures 14 to 16 illustrate the 
relationship between amount of NTH permeated per area and time for different 
concentration patches.  
 
5%patch 
Kp± S.E. [cm/h] ·10-3 r2 t0±S.E. [h] 
0,017± 0,00 0,999 56,835±1,94 
0,022± 0,00 0,992 48,880±2,87 
0,013± 0,00 0,999 47,188±1,35 
0,022± 0,00 0,992 52,188±3,54 
 
Standard two stage method: Kp=0.019·10-3±0.00 [cm/h]; t0=51.273±2.42[h] 
 
 
Table 10: NTH penetration through the human skin parameters (Kp-
permeability coefficient; r2-coefficient of the linear regression of 
experimental versus predicted data points; t0-lag time; S.E.-parameter 
standard error) 
 
 
 
 
 
7.5%patch 
Kp± S.E.[mg/cm] r2 t0±S.E.[h] 
0,010·10-3± 0,00 0,999 45,318±1,96 
0,003·10-3± 0,00 0,996 19,202±2,90 
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0,002·10-3± 0,00 0,968 33,667±2,24 
0,001·10-3±0,00 0,996 14,207±0,80 
 
Standard two stage method: Kp=0.004·10-3±0.00 [mg/cm]; t0=28.099±1.97[h] 
 
 
Table 11: NTH penetration through the human skin parameters (Kp-
permeability coefficient; r2-coefficient of the linear regression of 
experimental versus predicted data points; t0-lag time; S.E.-parameter 
standard error) 
 
10%patch 
Kp± S.E.[mg/cm] r2 t0±S.E.[h] 
0,005·10-3± 0,00 0,998 46,127±2,52 
0,007·10-3± 0,00 0,987 25,184±2,86 
0,003·10-3± 0,00 0,998 10,280±1,42 
0,003·10-3± 0,00 0,996 23,697±1,12 
 
Standard two stage method: Kp=0.005·10-3±0,00[mg/cm]; t0=26.312±1.98[h] 
 
 
Table 12: NTH penetration through the human skin parameters (Kp-
permeability coefficient; r2-coefficient of the linear regression of 
experimental versus predicted data points; t0-lag time; S.E.-parameter 
standard error) 
The extended lag time (around 50h) indicates that the steady state is not 
achieved during the experimental period. It is a drawback of the formulation 
presented that should be addressed in future designs. 
In order to increase the flux through the skin, the increase in patch 
concentration was assayed. The lag time is decreasing with increasing 
concentration.  As the Kp of 5%patch is anomalously high, the previous studies 
on NTH patches reported coefficients around 0.003 cm·h-1, only flux of 7.5% 
and 10% patches were calculated. The result is 0.834·10-6 [mg2cm/g] for 7.5% 
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patch and 1.291·10-6 [mg2cm/g] for 10%patch. It can be concluded that the 
increasing drug concentration increases the drug flux. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5%patch 
  50 
0 10 20 30 40 50
0
1
2
3
4
5
0 10 20 30 40 50
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0 10 20 30 40 50
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0 10 20 30 40 50
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0 10 20 30 40 50
0,0
0,5
1,0
1,5
2,0
2,5
3,0
 
 
Figure 14: penetration profile of NTH through the human skin; 5%patch; 
x=Q[mg/cm2]; y=t[h 
 
7.5%patch 
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Figure 15: Penetration profile of NTH through the human skin; 
7.5%patch; x=Q[mg/cm2]; y=t[h] 
 
10%patch 
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Figure 16: penetration profile of NTH through the human skin; 10%patch; 
x=Q[mg/cm2]; y=t[h] 
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5. SUMMARY AND CONCLUSIONS 
 
The object of this study was to investigate effect of NTH concentration 
incorporated in (hydroxypropyl)methyl cellulose patch on physical and 
biopharmaceutical properties of essayed films with a intended aim to develop 
controlled drug release system to help smokers to quit. 
Using NTH, antidepressant drug, in the smoking cessation is secure, with a 
good tolerance a lower cost, if we compare it with others substances, like 
bupropion, recommended in the specialized bibliography as alternative for the 
first line treatment. 
As described in the theoretical part, selection of the transdermal route is based 
on the appropriate physical-chemical properties of the drug and better patient’s 
compliance for this type of administration than for oral route. 
Between different possibilities of the transdermal delivery system, drug-in-matrix 
design principle was chosen. It’s technologically easier to prepare small scale. 
Besides that it’s more economic than the other designs, question relevant for 
pharmaceutical form with presumptive commercialization. Moreover, because of  
its thinness, it’s more discrete for patients to apply.  
 Essential patch constituent, (hydroxypropyl)methyl cellulose (HPMC), was 
selected because it is an atoxic polymer which provides transparent films with 
good organoleptic properties. Its safety profile is well established through a 
large experience in its use. Furthermore, the desired adhesiveness can be 
achieved by changing its concentration in the matrix. 
Patches of 5%, 7.5% and 10% NTH concentrations were studied for the 
physical, release and penetration characteristics. 
According to the presented results it can be concluded that the thickness 
remains constant regardless of the NTH concentration of the gel used to 
prepare the film. The homogeneity of the films was macroscopically established.   
The maximum cumulative amount released at the last sampling point varies as 
a function of the NTH concentration in the patch. Nevertheless there is not a 
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clear relationship between percentage released and patch concentration. This 
might be explained by retention of NTH by the matrix of HPMC.  
From reported results, it seems evident that both assayed kinetic models, first 
order and power law, are useful in order to predict the amount released and the 
rate at which the process will be developed. The release mechanism is basically 
fickian diffusion.  
Considering penetration experiments, the above-described results have shown 
that the lag time decreases with increasing patch concentration, so that only 7.5 
and 10% NTH patch are promising. Taking into account that the provided flux 
depends directly on the concentration, the conclusion is that 10%patch is the 
design to be develop a TDS useful practice.  
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6. ABREVIATIONS 
  
 
  EtOH Ethanol 
FDC Franz diffusion cells 
HPMC (Hydroxypropyl)methyl cellulose 
HSE Heat separated epidermis 
NaCl Sodium chloride 
NAD Naïve Averaging Data 
NTH Nortriptyline Hydrochloride 
STS Standard Two Steps method 
TDS Transdermal Drug delivery System 
WHO World Health Organization 
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